Weijing Sun, MD, discusses a major topic in locally advanced gastroesophageal junction adenocarcinoma covered at the 2018 ISGIO Annual Conference in Arlington, Virginia.
Weijing Sun, MD, gastrointestinal oncologist at the University of Kansas School of Medicine, discusses a major topic in locally advanced gastroesophageal junction (GEJ) adenocarcinoma covered at the 2018 ISGIO Annual Conference in Arlington, Virginia.
At the conference, experts debated the role of radiation therapy in this patient population, Sun says. Two studies looked at different preoperative therapy options with encouraging data both with and without radiation.
The FLOT study explored a regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel for this patient population, without radiation. The CROSS study looked at the combination of carboplatin and paclitaxel with radiation.
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
March 27th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More